Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma

European Journal of Clinical Investigation

Volumn 43, Issue 12, 2013, Pages 1282-1290

  Urbschat, Anja ^a   Paulus, Patrick ^a   von Quernheim, Quirine Freiin ^a   Brück, Patrick ^b   Badenhoop, Klaus ^a   Zeuzem, Stefan ^a   Ramos Lopez, Elizabeth ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Clear cell renal cell carcinoma; CYP24A1; CYP27B1; CYP2R1; Vitamin D

Indexed keywords

CALCITRIOL; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; CYTOCHROME P450 2R1; MESSENGER RNA; OXYGENASE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; MALE; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITAMIN D METABOLISM;

CLEAR CELL RENAL CELL CARCINOMA; CYP24A1; CYP27B1; CYP2R1; VITAMIN D;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHOLESTANETRIOL 26-MONOOXYGENASE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, MESSENGER; STEROID HYDROXYLASES; UP-REGULATION;

EID: 84888049796     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12176     Document Type: Article

References (39)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-71.
4. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-23.
5. Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Negrier S et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 2011;17:5443-50.
6. Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. Front Endocrinol (Lausanne) 2012;3:58.
7. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-52.
8. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC et al. Plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1991-7.
9. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989;2:1176-8.
10. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009;19:468-83.
11. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-91.
12. Burgi AA, Gorham ED, Garland CF, Mohr SB, Garland FC, Zeng K et al. High serum 25-hydroxyvitamin D is associated with a low incidence of stress fractures. J Bone Miner Res 2011;26:2371-7.
13. Fujioka T, Suzuki Y, Okamoto T, Mastushita N, Hasegawa M, Omori S. Prevention of renal cell carcinoma by active vitamin D3. World J Surg 2000;24:1205-10.
14. Karami S, Brennan P, Rosenberg PS, Navratilova M, Mates D, Zaridze D et al. Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS ONE 2009;4:e7013.
15. Arjumand W, Ahmad ST, Seth A, Saini AK, Sultana S. Vitamin D receptor FokI and BsmI gene polymorphism and its association with grade and stage of renal cell carcinoma in North Indian population. Tumour Biol 2012;33:23-31.
16. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999;96:507-15.
17. Buentig N, Stoerkel S, Richter E, Dallmann I, Reitz M, Atzpodien J. Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma. Cancer Biother Radiopharm 2004;19:331-42.
18. Sakaki T, Sawada N, Komai K, Shiozawa S, Yamada S, Yamamoto K et al. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem 2000;267:6158-65.
19. Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T. Expression of vitamin D3 receptor in kidney tumors. Hum Pathol 2006;37:1268-78.
20. Madej A, Puzianowska-Kuznicka M, Tanski Z, Nauman J, Nauman A. Vitamin D receptor binding to DNA is altered without the change in its expression in human renal clear cell cancer. Nephron Exp Nephrol 2003;93:e150-7.
21. Zehnder D, Bland R, Walker EA, Bradwell AR, Howie AJ, Hewison M et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol 1999;10:2465-73.
22. Blomberg Jensen M, Andersen CB, Nielsen JE, Bagi P, Jorgensen A, Juul A et al. Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J Steroid Biochem Mol Biol 2010;121:376-82.
23. Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract 2004;58:333-6.
24. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 1994;31:191-202.
25. Cross HS, Bajna E, Bises G, Genser D, Kallay E, Potzi R et al. Vitamin D receptor and cytokeratin expression may be progression indicators in human colon cancer. Anticancer Res 1996;16:2333-7.
26. Kane KF, Langman MJ, Williams GR. 1, 25-Dihydroxyvitamin D3 and retinoid X receptor expression in human colorectal neoplasms. Gut 1995;36:255-8.
27. Magrassi L, Bono F, Milanesi G, Butti G. Vitamin D receptor expression in human brain tumors. J Neurosurg Sci 1992;36:27-30.
28. King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N. The vitamin D/CYP24A1 story in cancer. Anti-Cancer Agents Med Chem 2010;10:213-24.
29. Luo W, Hershberger PA, Trump DL, Johnson CS. 24-Hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol 2013;136:252-7.
30. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006;57:234-40.
31. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 2005;11:3579-86.
32. Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 2006;119:1819-28.
33. Welsh J, Vitamin D. metabolism in mammary gland and breast cancer. Mol Cell Endocrinol 2011;347:55-60.
34. Horvath HC, Lakatos P, Kosa JP, Bacsi K, Borka K, Bises G et al. The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 2010;58:277-85.
35. Iida K, Taniguchi S, Kurokawa K. Distribution of 1, 25-dihydroxyvitamin D3 receptor and 25-hydroxyvitamin D3-24-hydroxylase mRNA expression along rat nephron segments. Biochem Biophys Res Commun 1993;194:659-64.
36. Omdahl JL, Bobrovnikova EA, Choe S, Dwivedi PP, May BK. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids 2001;66:381-9.
37. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004;29:664-73.
38. Nagakura K, Abe E, Suda T, Hayakawa M, Nakamura H, Tazaki H. Inhibitory effect of 1 alpha, 25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int 1986;29:834-40.
39. Lambert JR, Eddy VJ, Young CD, Persons KS, Sarkar S, Kelly JA et al. A vitamin D receptor-alkylating derivative of 1alpha, 25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) 2010;3:1596-607.